Please login to the form below

Not currently logged in
Email:
Password:

Prostrakan and Bayer Schering enter testosterone partnership

UK speciality pharmaceutical company ProStrakan has announced that it has granted Bayer Schering an exclusive license to develop and commercialise its testosterone gel

UK speciality pharmaceutical company ProStrakan has announced that it has granted Bayer Schering an exclusive license to develop and commercialise its testosterone gel, Tostran in 65 countries worldwide.

Tostran is a testosterone gel indicated for testosterone replacement therapy in men with hypogonadism, a condition where the testes fail to produce androgen and/or sperm.

Under the terms of the agreement, Bayer Schering will make an undisclosed upfront payment to ProStraken, which will be followed by milestone payments subject to certain approvals and sales targets being met.

Dr Wilson Totten, ProStrakan's chief executive, said: “Outlicensing Tostran to Bayer Schering Pharma in these territories is in line with our strategy of capitalising on the value of our products in parts of the world that are non-core for ProStrakan. In Bayer Schering Pharma, we have a worthy and sizeable partner with a deep understanding of the testosterone replacement market who is well-placed to bring this product to clinicians in each of these territories.”

Tostran is currently marketed in Europe under several brand names including Tostran, Tostrex and Itnogen. The product will be branded Fortigel in the US.

27th November 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Wisepress

Wisepress is a medical bookseller promoting and selling books worldwide, both online and via the 200 European medical conferences that...

Latest intelligence

Is the pharma business model ready for precision medicine?
Precision medicine promises to revolutionise patient outcomes and reduce costs for industry but is pharma ready for it? Blue Latitude Health co-founder Head of Strategy Fred Bassett explores the challenges...
ABPI2018
The NHS and ABPI at 70: inching closer to the triple win
The NHS and UK pharma’s ABPI both turn 70 this year. After years of transactional relationships, there’s a will to work more closely - but friction on prices and value...
What pharma marketers can learn from behavioural science
Pharma behavioural science and traditional emotional marketing create a powerful mix of techniques that have impact on real lives....

Infographics